News & Updates

Patients with AHP who do not achieve an attack-free status after the first 6 months of givosiran treatment can still benefit from further attack reductions and QoL improvements with continued treatment up to 36 months, according to the results from the ENVISION trial presented at EASL 2024

Evaluation of CXCL13 concentration in cerebrospinal fluid (CSF) shows good diagnostic accuracy for neurosyphilis, according to the results of a systematic review and meta-analysis.

Increased practice of Chinese calligraphy strengthens brain network in older individuals who already practice the cognitive activity regularly and experienced subjective cognitive decline (SCD), a two-arm, parallel-design, assessor-blind, randomized controlled trial conducted by the Chinese University of Hong Kong (CUHK) has found.

High-dose supplementation of docosahexaenoic acid (DHA) in breastfeeding mums did not improve behavioural functioning and neurodevelopmental outcomes at 5 years in children born very preterm. However, it may be of benefit to some subgroups of children, according to the results of the 5-year follow-up of a subgroup from the MOBYDIck* trial.